Novartis Receives FDA Approval for Cosentyx in Hidradenitis Suppurativa

Novartis today announced that the FDA has approved Cosentyx (secukinumab) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In the Phase 3 SUNSHINE and SUNRISE trials, Cosentyx demonstrated statistically significant improvements in the HiSCR50 response rate compared to placebo. Cosentyx is an IL-17A inhibitor that targets a key inflammatory cytokine involved in HS pathogenesis. This approval expands Cosentyx's use into HS, adding to its existing approvals in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.